Article

FDA Approves New Fast-Acting Mealtime Insulin

Officials with the FDA have approved fast-acting insulin aspart (Fiasp, Novo Nordisk) for the treatment of adults with diabetes.

Officials with the FDA have approved fast-acting insulin aspart (Fiasp, Novo Nordisk) for the treatment of adults with diabetes. Fiasp is a fast-acting mealtime insulin designed for individuals in need of improved overall glucose control.

Fiasp, a formulation of insulin aspart, was developed to more closely match the physiological insulin mealtime response of an individual with diabetes. Vitamin B3 (niacinamide) and a naturally occurring amino acid (L-Arginine) were added to increase the speed of absorption and for stability, respectively.

The approval is based on clinical trials that demonstrated Fiasp’s clinically relevant improvement in long-term glucose level. The trial researchers noted comparable overall rate of severe or blood sugar confirmed hypoglycemia between Fiasp and aspart. The phase 3 clinical program included 4 trials with more than 2100 individuals with type 1 and type 2 diabetes.

According to data presented recently at the 53rd European Association for the Study of Diabetes Annual Meeting, in the onset 1 trial, Fiasp was compared to conventional insulin aspart in type 1 diabetes over a 52-week study, split in two 26-week treatment periods. Over the 52-week period, Fiasp demonstrated a statistically significant greater overall blood sugar reduction of -0.10% adults with type 1 diabetes, in comparison to conventional insulin aspart. Fiasp also demonstrated a statistically significant reduction in 1-hour post-meal sugar increment of -0.91 mmol/L. However, no significant differences were noted in 2-hour post-meal sugar increment compared with conventional insulin aspart.

Novo Nordisk received a Complete Response Letter (CRL) from the FDA for Fiasp in October 2016, and later resubmitted the new drug application on March 29, 2017.

In this video taken during a satellite symposium held by PTCE in conjunction with APHA2017, Jennifer Goldman, PharmD, discusses the diabetes drug pipeline and the promise it holds for treating patients with type 2 diabetes in the future.

References

Novo Nordisk’s new fast-acting mealtime insulin Fiasp approved in the US [company announcement]. Denmark. http://hugin.info/2013/R/2138112/818474.pdf. Accessed September 29, 2017.

Fiasp significantly improved overall blood sugar control in type 1 diabetes long-term [news release]. Lisbon. Novo Nordisk. https://globenewswire.com/news-release/2017/09/12/1117883/0/en/Fiasp-significantly-improved-overall-blood-sugar-control-in-type-1-diabetes-long-term.html. Accessed September 29, 2017.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com